Native tumor biology
In vivo immunization using tumor cells and engineered approaches
Our platform
A more precise view of opportunity starts at the epitope.
TenSixty studies epitope-level differences that may not be resolved by protein-level measurements, creating a more precise foundation for oncology therapeutics.
Why epitopes
The same protein can present a different therapeutic opportunity.
Tumor and healthy cells can display distinct proteoforms of the same protein. Those differences can change which epitopes are exposed and available for therapeutic binding.
- Cell state and post-translational context shape epitope accessibility.
- Tumor-selective biology may be hidden by protein-level measurements.
- Finding the right epitope can optimize the therapeutic index.
Platform architecture
One connected architecture, from native tumor biology to epitope-defined leads.
GlycoLens and Atlas xTI inform a functional antibody discovery engine, while a unified data layer keeps epitopes, binders, antigens, and function connected.
Target & proteoform discovery engine
01
02
GlycoLens™
Proteoform-level epitope discovery
Atlas xTI™
Therapeutic-index modeling in single-cell and tissue context
Epitope-defined therapeutic discovery engine
-
01
Single-cell B cell capture
-
02
Multiplexed tumor-vs-healthy screening
-
03
Map antigen and epitope
-
04
Validate and optimize therapeutic index
-
05
Select epitope-defined leads
Epitope-defined antibodies with improved therapeutic index
- Candidates ranked by real tumor selectivity
- Binders mapped to antigen, epitope, and function
Complementary discovery engines
Determine what to target—and where.
Direct measurement and predictive prioritization work together to move from native disease biology to actionable therapeutic hypotheses.
GlycoLens™
Resolves disease-state proteoforms and the epitopes they present, revealing tumor-associated biology that conventional antigen views may not distinguish.
Asks
Which proteoforms and epitopes are tumor-selective?
Reads
Native abundance, occupancy, and proteoform context
Produces
Candidate therapeutic epitopes for binder discovery
Atlas xTI™
Places each opportunity in tumor, healthy-tissue, and therapeutic context to help prioritize targets, indications, combinations, and modality fit.
Asks
Where can an epitope create meaningful selectivity?
Models
Coverage, prevalence, tissue context, and modality fit
Produces
Prioritized opportunities and development guidance
Native biology to lead
A functional path to epitope-defined therapeutics.
The workflow preserves native tumor context while linking every binder to its antigen, epitope, and functional profile.
Resolve native biology
Profile tumor-associated proteoforms and place them in healthy-tissue and single-cell context.
Discover selective binders
Generate and screen antibodies against native tumor biology to enrich for tumor-selective binding.
Map antigen and epitope
Connect binder sequence and function to the precise molecular feature each antibody recognizes.
Validate and select leads
Integrate selectivity, internalization, and developability evidence to nominate epitope-defined therapeutic leads.
Unified data flywheel
Every campaign can make the next decision better informed.
TenSixty connects native tumor biology, single-cell context, therapeutic epitopes, antibody identity, and functional performance in one evolving data foundation.
Ground truth from discovery and validation feeds back into subsequent campaigns, strengthening how new opportunities are ranked and pursued.
Modality flexibility
Start with the biology. Choose the right therapeutic format.
Epitope-defined binders can support multiple antibody-based modalities, allowing format selection to follow the target biology and clinical opportunity.
Antibody-drug conjugates
Pair tumor-selective binding with a payload strategy suited to the target and disease setting.
T-cell engagers
Use epitope-level specificity as the targeting foundation for redirected immune activity.
Multispecifics
Combine complementary binding logic to address tumor context with greater design flexibility.
From platform to pipeline
Explore the pipeline